Jorcyk, Cheryl L. - Boise State University - Department of Biological Sciences

个人简介

B.S. in Biology, Pennsylvania State University, State College, PA, 1983 Ph.D. in Biology, The Johns Hopkins University, Baltimore, MD, 1991 Postdoctoral Fellowship, Intramural Research Training Award, National Cancer Institute, National Institutes of Health, 1992-1997

研究领域

My laboratory’s research interests are directed towards elucidation of the molecular mechanisms that promote tumor progression. We have been working on the effects of the cytokine Oncostatin M (OSM) on breast tumor progression and metastasis. Oncostatin M (OSM), an IL-6 family cytokine, is produced by breast cancer cells and tumor-associated cells of the immune system, including macrophages and neutrophils. OSM has been shown to inhibit the proliferation of breast cancer cells, and this effect initially focused much attention on OSM as a potential breast cancer therapy. Data from our lab, however, suggests that OSM could actually contribute to tumor progression and the development of a metastatic state. We have shown that OSM induces vascular endothelial cell growth factor (VEGF), cyclooxygenase-2 (COX-2), cell detachment, and invasive capacity in vitro. In vivo studies have confirmed an important role for OSM in breast cancer metastasis to bone. Studies investigating OSM in prostate cancer are underway.

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Goyden J, Tawara K, Hedeen D, Wiley J, Oxford JT, and Jorcyk CL. The effect of OSM on MC3T3-E1 osteoblastic cells in simulated microgravity with radiation. PLoS ONE. In press. Cannon B, Hiremath M, Jorcyk C, and Joshi A. CoVE: Colony visualization system for animal pedigrees. Visual Information Communication an Interaction (VINCI). In press. Ryan RE, Martin B, Mellor L, Jacob RB, Tawara K, McDougal OM, Oxford JT, Jorcyk CL. Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis. Cytokine 72(1), 71-85, 2015. PMID: 25622278 Mikelonis D, Jorcyk, CL, Tawara, K, Oxford JT. Stuve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology. Orphanet J Rare Dis. 9, 1-11, 2014. PMID: 24618404 Nadelson, L, Jorcyk, C, Yang, D, Smith, J, Matson, S, Cornell, K, and Husting, V. “I Just Don’t Trust Them: The Development and Validation of an Assessment Instrument to Measure Trust in Science and Scientists”. School Science and Mathematics, 114(2), 76-86, 2014. Bolin, C, Tawara, K, Sutherland, C, Redshaw, J, Aranda, P, Moselhy, J Anderson, R, and Jorcyk C.L. Oncostatin M promotes mammary tumor metastasis to bone and osteolytic bone degradation. Genes Cancer 3, 117-30, 2012. PMID: 23050044 Bolin, C., Sutherland, C., Tawara, K., and Jorcyk, C.L. Novel mouse mammary cell lines for in vivo bioluminescence imaging (BLI) of bone metastasis. Biol Proced 14, 6-12, 2012. PMID: 22510147. Jorcyk, C.L., Kolev, M., Tawara, K., and Zubik-Kowal, B. Experimental versus numerical data for breast cancer progression. Journal of Nonlinear Analysis: Real World Applications 13, 78-84, 2012. Aranda P.S., LaJoie D.M., Jorcyk C.L. Bleach gel: a simple agarose gel for analyzing RNA quality. Electrophoresis 33, 366-9, 2012. PMID: 22222980 Tawara, K. and Jorcyk, C.L. Clinical significance of interleukin-6 (IL-6) in cancer metastasis to bone: potential of anti-IL-6 therapies. Cancer Management and Research 3, 177-89, 2011. PMID: 21625400 Zubik-Kowal, B., Jorcyk, C.L., and Kolev, M. Numerical experiments for mammary adenocarcinoma cell progression. Integral Methods in Science and Engineering, Springer, 2011, book chapter. Graugnard, E., Cox, A., Lee, J., Jorcyk, C.L., Yurke, B., and Hughes, W.L. Operation of a DNA-based autocatalytic network in serum. Lecture Notes in Computer Science, 6518, 83, 2011. Graugnard, E., Cox, A., Lee, J., Jorcyk, C.L., Yurke, B., and Hughes, W.L. Kinetics of DNA and RNA hybridization in serum and serum-SDS. IEEE Transactions on Nanotechnology 9, 603, 2010. PMID: 20967137 Jackiewicz, Z., Jorcyk, C.L., Kolev, M., and Zubik-Kowal, B. Correlation between animal and mathematical models for prostate cancer progression. Computation and Mathematical Methods in Medicine iFirst article, 1-12, 2009. Halsted, KC, Bowen, KB, Bond, L, Jorcyk, CL, Fyffe, WE, Kronz, JD, Oxford, JT. Collagen alpha1(XI) in normal and malignant breast tissue. Modern Pathology 21:1246-54, 2008. Jorcyk, C.L., Holzer, R.G., and Ryan, R.E.: Oncostatin M induces detachment and enhanced metastatic capacity in T-47D human breast carcinoma cells. Cytokine 33:323-336, 2006. Queen, M.M., Ryan, R.E., Holzer, R.G., Keller-Peck, C.R., and Jorcyk, C.L.: Breast cancer cells stimulate neutrophils to produce Oncostatin M: potential implications for tumor progression. Cancer Research 65: 8896-8904, 2005. MacDougall, C.A., Ide, A., Soares, C., Vargas, M., Holzer, R.G., and Jorcyk, C.L.: Involvement of the hepatocyte growth factor-met receptor signaling loop with the classical “3M” pathways in tumor progression of mouse prostate adenocarcinoma cells. The Prostate 64: 139-149, 2005. Holzer, R.G., Tommack, M., Schlekeway, E., Ryan, R.E, and Jorcyk, C.L: Oncostatin M induces the detachment of a reservoir of invasive mammary carcinoma cells: the role of cyclooxygenase-2. Clinical and Experimental Metastasis 21:167-176, 2004. Holzer, R.G., MacDougall, C., Atwood, C., Green, J.E., and Jorcyk, C.L. 2003. Development and characterization of a progressive series of hormone-responsive mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model. Breast Cancer Research and Treatment 77:65-76. Soares, C., Shibata, M.-A., Green, J.E. and Jorcyk, C.L.: 2002. Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression. Neoplasia 4: 112-120. Calvo, A., Xiao, N., Simon, R., Kang, J., Best, C., Emmert-Buck, M., Jorcyk, C.L., and Green, J.E. 2002. Identification of genes in prostate tumor progression by cDNA microarray analysis in an in vitro model derived from C3(1)/T-antigen transgenic mice: down-regulation of selenoprotein-P in mouse and human prostate cancer. Cancer Research 62: 5325-35. Wigginton, J.M., Park, J.W., Gruys, M.E., Young, H.A., Jorcyk, C.L., Back, T.C., Brunda, M.J., Strieter, R.M., Ward, J., Green, J.E. and Wiltrout, R.H. 2001. Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, fas/fas ligand gene expression, and mammary epithelial apoptosis. J. Immunol. 166: 1156-1168. Green, J.E., Shibata, M.A., Yoshidome, K., Kiu, M.L., Jorcyk, C., Anver, M.R., Wigginton, J., Wiltrout, R., Shibata, E., Kaczmarczyk, S., Wang, W., Liu, Z.Y., Calvo, A. and Couldrey, C. 200. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19: 1020-1027. Shibata, M.-A., Yoshidome, K., Shibata, E., Jorcyk, C.L. and Green, J.E. 2000. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Therapy 1: 1-10.